Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 272.66B +15.1% |
| Revenue (ttm) | 63.36B +1.5% |
| Net Income | 12.88B +55.6% |
| EPS | 16.04 +55.6% |
| Shares Out | 795.62M |
| PE Ratio | 21.27 |
| Forward PE | 16.86 |
| Dividend | 9.80 (2.87%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 1,214,998 |
| Average Volume | 1,089,069 |
| Open | 320.00 |
| Previous Close | 341.20 |
| Day's Range | 315.60 - 330.40 |
| 52-Week Range | 231.90 - 374.90 |
| Beta | 0.21 |
| RSI | 30.21 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsNews
Roche's Breast Cancer Drug Falls Short In Phase 3 Study
Roche Holdings AG (OTC: RHHBY) on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients . Trial Misses Primary Goa...
Roche (RHHBY) Shares Drop After Breast Cancer Drug Trial Misses Goal
Roche (RHHBY) Shares Drop After Breast Cancer Drug Trial Misses Goal
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
Roche Shares Drop Up to 7.5% After Breast Cancer Pill Misses Trial Goal
Roche shares drop as oral breast cancer drug fails in trial
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate giredestrant against a common form of breast cancer can help newly diagnosed pa...
Genentech: PersevERA Breast Cancer Study Fails To Meet Primary Objective
(RTTNews) - Genentech, a member of the Roche Group (RO.SW, ROG.SW), announced results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbo...
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study
The combination of Roche's investigational drug, giredestrant, with Pfizer's Ibrance didn't lead to a statistically significant improvement among patients with advanced breast cancer.
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating i...
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer
Basel, 9 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbocicli...
2 Underrated Weight Loss Stocks to Buy Now
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duti...
Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus ery...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (...
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has th...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms G azyva has the potential to be...
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
Roche and Zealand Pharma's obesity drug petrelintide showed up to 11% weight loss in a Phase 2 trial with strong safety results. ... Full story available on Benzinga.com
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Roche's Petrelintide Achieves Over 100% Weight Loss In Phase 2 Trial
(RTTNews) - Roche (RHHBY) announced positive topline results from its Phase 2 ZUPREME-1 study of Petrelintide, an investigational amylin analog for people living with overweight and obesity.
Roche's (RHHBY) Genentech Reports Positive Trial Results for Obesity Drug
Roche's (RHHBY) Genentech Reports Positive Trial Results for Obesity Drug
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial
Genentech, part of Roche , said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 peopl...
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating...
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1 Majority of respondents say that con...
Roche (RHHBY) Targets Top Position in Weight Loss Drug Market
Roche (RHHBY) Targets Top Position in Weight Loss Drug Market